Sun Yat-sen University — Clinical Trial Pipeline

Sun Yat-sen University has 16 registered trials in the index.

Trials (16)

• PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC Phase 3 · Sun Yat-sen University
• A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC Phase 3 · Sun Yat-sen University
• SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Phase 2 · Sun Yat-sen University
• Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma. Phase 2 · Sun Yat-sen University
• HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC Phase 3 · Sun Yat-sen University
• Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients N/A · Sun Yat-sen University
• Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC Phase 2 · Sun Yat-sen University
• Predictive Value of Postoperative Circulating Tumor DNA Monitoring for Colorectal Cancer Recurrence N/A · Sun Yat-sen University
• A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients N/A · Sun Yat-sen University
• Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. Phase 1 · Sun Yat-sen University
• Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer Phase 3 · Sun Yat-sen University
• Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. Phase 2 · Sun Yat-sen University
• Olfactory Change After Chemo-radiotherapy for Nasopharyngeal Carcinoma N/A · Sun Yat-sen University
• Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial Phase 3 · Sun Yat-sen University
• A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma Phase 2 · Sun Yat-sen University
• HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial Phase 2 · Sun Yat-sen University

Related landscapes

• Nasopharyngeal Carcinoma
• Hepatocellular Carcinoma
• Colorectal Cancer
• Nasopharangeal Cancer
• Distant Metastasis

Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.